REG3A

Across TCGA pan-cancer cohorts, REG3A Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated REG3A data layer compared with 17 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher REG3A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated REG3A expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

ACC, ESCA, and STAD are the cancer types where REG3A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.010	0.667	<.001	45	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	21	view →
STAD	OS	Median	II,III,IV	0.184	0.710	.001	21	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	OS	Median	IV	0.243	0.602	.026	6	view →
LUSC	DFS	Median	II,III,IV	0.640	0.327	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

REG3A–ACC (DFS)

Open the ACC breakdown →